Quanterix, a company developing technology designed to enable earlier disease detection, made its market debut on Thursday. Shares of the company surged after pricing at $15 a share, and opening at $16.25 a share. Kevin Hrusovsky, CEO of Quanterix, was with us to discuss how the company plans to revolutionize healthcare. The fourth-leading cause of death is drug side effects, and drugs only work half the time, says Hrusovsky. He believes that if you can personalize the drugs, you have an opportunity to improve the whole pharmaceutical industry. Quanterix is developing technology that will digitize how they see into blood, and help to see disease long before there are symptoms. Rocket science is being deployed into the blood, says Hrusovsky. He says that if you can see biomarkers and incorporate into fitbits, it can really help improve health.

Share:
More In Science
Good2Know: Study Says Loneliness May Reduce Bone Density in Men
A new study on loneliness is showing it may not only affect mental health, but it may also be bad for the bones. However, the study found it impacts one group in particular: men. Amid concerns about the rising epidemic of loneliness, researchers wanted to take a closer look at its effects.
Cancer Patients Face Shortage of Chemotherapy Drugs
The American Cancer Society estimates that over 20,000 new cancer cases in Connecticut this year alone. But there's a concerning shortage of chemotherapy drugs in the state and across the country. News 12 reporter Mark Sudol tells us why and what can be done.
Load More